UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 920

Sortiert nach

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Journal of medicinal chemistry, 2019-06, Vol.62 (11), p.5522-5540

2019

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Nature communications, 2019-04, Vol.10 (1), p.1911-13, Article 1911

2019

Link zum Volltext

Verfügbarkeit prüfen

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

Frontiers in oncology, 2020-05, Vol.10, p.636-636

2020

Link zum Volltext

Verfügbarkeit prüfen

Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response

Nature communications, 2023-08, Vol.14 (1), p.5029-5029, Article 5029

2023

Link zum Volltext

Verfügbarkeit prüfen

Clonal hematopoiesis in myeloma: root of all maladies

Blood, 2020-06, Vol.135 (26), p.2330-2331

Neri, Paola

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune Deregulation in Active Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.SCI5-SCI5

Neri, Paola

2020

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors

Blood, 2011-12, Vol.118 (24), p.6368-6379

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma

Current cancer drug targets, 2012-09, Vol.12 (7), p.776

2012

Link zum Volltext

Verfügbarkeit prüfen

Understanding the Mechanisms of Resistance to T Cell‐based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma

HemaSphere, 2021-06, Vol.5 (6), p.e575-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

The Pandora's box of thalidomide analogs and their substrates

Blood, 2019-07, Vol.134 (2), p.105-106

Neri, Paola

2019

Link zum Volltext

Verfügbarkeit prüfen

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

Blood, 2011-06, Vol.117 (23), p.6202-6213

2011

Link zum Volltext

Verfügbarkeit prüfen

Genomic instability in multiple myeloma: mechanisms and therapeutic implications

Expert opinion on biological therapy, 2013-06, Vol.13 (S1), p.S69-S82

2013

Link zum Volltext

Verfügbarkeit prüfen

Enhancer Deregulation in Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.SCI-38-SCI-38

Neri, Paola

2018

Link zum Volltext

Verfügbarkeit prüfen

CRISPRing the CRL4CRBN RING in multiple myeloma

Blood, 2018-09, Vol.132 (12), p.1219-1220

Neri, Paola

2018

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma

Annals of hematology, 2017-03, Vol.96 (3), p.431-439

2017

Link zum Volltext

Verfügbarkeit prüfen

Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

Clinical cancer research, 2012-09, Vol.18 (18), p.4962-4972

2012

Link zum Volltext

Verfügbarkeit prüfen

Localized Surface Plasmon Resonance Detection of Biological Toxins Using Cell Surface Oligosaccharides on Glyco Chips

ACS applied materials & interfaces, 2013-05, Vol.5 (10), p.4173-4180

2013

Link zum Volltext

Verfügbarkeit prüfen

Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma

Critical reviews in oncology/hematology, 2023-08, Vol.188, p.104041-104041, Article 104041

2023

Link zum Volltext

Verfügbarkeit prüfen

Revised International Staging System applied to Real World Multiple Myeloma Patients

Clinical lymphoma, myeloma and leukemia, 2016-09, Vol.16 (9), p.511-518

2016

Link zum Volltext

Verfügbarkeit prüfen

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Cancer research (Chicago, Ill.), 2006-07, Vol.66 (13), p.6675-6682

2006

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance

Mediterranean journal of hematology and infectious diseases, 2019, Vol.11 (1), p.e2019007-e2019007

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma

The journal of pathology. Clinical research, 2020-10, Vol.6 (4), p.252-262

2020

Link zum Volltext

Verfügbarkeit prüfen

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

Cancer research (Chicago, Ill.), 2005-09, Vol.65 (18), p.8350-8358

2005

Link zum Volltext

Verfügbarkeit prüfen

MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

Clinical cancer research, 2006-10, Vol.12 (19), p.5887-5894

2006

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model

Clinical cancer research, 2007-10, Vol.13 (19), p.5903-5909

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 920

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(829)
Mit Volltextzugriff
(849)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(176)
Clinical Lymphoma, Myeloma And Leukemia
(22)
Gastroenterology
(15)
Cancer Research
(11)
Clinical Cancer Research
(11)
Haematologica
(9)
Plos One
(9)
Cancers
(8)
Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles
(7)
Leukemia & Lymphoma
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response

Clonal hematopoiesis in myeloma: root of all maladies

Immune Deregulation in Active Multiple Myeloma

Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma

Understanding the Mechanisms of Resistance to T Cell‐based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma

The Pandora's box of thalidomide analogs and their substrates

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

Genomic instability in multiple myeloma: mechanisms and therapeutic implications

Enhancer Deregulation in Myeloma

CRISPRing the CRL4CRBN RING in multiple myeloma

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma

Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

Localized Surface Plasmon Resonance Detection of Biological Toxins Using Cell Surface Oligosaccharides on Glyco Chips

Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma

Revised International Staging System applied to Real World Multiple Myeloma Patients

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model

Suchergebnisse filtern